Silencing the
virus within
L1 Therapeutics is developing precision therapies that suppress LINE-1 - an ancient virus-like element in the human genome that reactivates under stress and contributes to disease
Targeting LINE-1, an ancient virus-like element in the human genome
When LINE-1 reactivates under stress, it drives genomic instability and an innate immune reaction. Because LINE-1 stays quiet in healthy tissue, inhibitors primarily target disease-causing cells
Therapeutic strategy
New technology now lets us identify diseases where LINE-1 activity is treatable. We focus on conditions that show genomic signs of ongoing, active LINE-1 biology contributing significantly to disease
Building strategic collaborations
L1 Therapeutics is advancing its therapeutic strategy with the intent to collaborate with pharmaceutical and diagnostics partners on programs across rare neurological disease, oncology, and aging biology
Short reads on LINE-1 biology
Open-source retrotransposon mining
retrotransposon-miner is our open-source software for finding mobile DNA insertions in genomic data. It detects insertions that earlier methods miss, including events previously thought to require long-read sequencing or that were not detectable before
View on GitHub
Scientific, partnering, or investment inquiries
We welcome conversations with pharmaceutical and diagnostics partners, scientific collaborators, and investors aligned with our mission
info@l1tx.com